OpenEvidence, AI Medical Research Startup, Reaches $12 Billion Valuation in Early 2026

OpenEvidence reached a valuation of $12 billion after an early 2026 funding round, the company cofounded by Daniel Nadler to apply artificial intelligence to the challenge of digesting voluminous medical research. The company was founded to use AI to help doctors make sense of the voluminous amount of medical research.

The funding round that set OpenEvidence's $12 billion valuation occurred in early 2026. Nadler owns nearly 60% of OpenEvidence. 2 billion at the new valuation.

@Forbes reported the valuation, ownership details and founding purpose of the company. The early 2026 round comes less than four years after Nadler launched the startup, underscoring the speed with which investors have embraced tools that promise to organize and interpret the expanding universe of biomedical literature.

OpenEvidence's core proposition addresses a practical problem for physicians: the sheer volume of new studies, trials and regulatory updates published each year.

By applying large language models and specialized retrieval systems, the platform aims to surface relevant findings without requiring doctors to conduct exhaustive manual searches. The $12 billion post-money valuation places OpenEvidence among the most valuable private AI companies founded in the past decade.

Nadler's nearly 60% ownership reflects both his role as cofounder and the relatively modest dilution seen through the company's early funding stages.

No further financial terms of the early 2026 round, including the amount raised or lead investors, were disclosed in the available reporting. The company has not commented publicly on customer adoption metrics or revenue at the time of the valuation announcement.